Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

More patients treated with isatuximab, bortezomib, lenalidomide, and dexamethasone had improved progression-free survival and had a complete or better response than those treated with VRd alone.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology